Quantitative Analysis of HER2 Amplification by Droplet Digital PCR in the Follow-Up of Gastric Cancer Patients Being Treated with Trastuzumab after Surgery

Table 1

Clinicopathological characteristics of all patients.

Patient ID	Age	Gender	Tumor location	Tumor size (cm)	Differentiation	Lymph node metastasis	Distant metastasis	Stage	TNM	Treatment
1	53	Female	Antrum	4	Poor	Positive	Liver	IV	T4aNxM1	FOLFOX+trastuzumab
2	36	Male	Antrum	4.5	Poor	Positive	Peritoneum	IV	T4N1M1	FOLFOX+trastuzumab
3	64	Female	Cardia	4	Moderate	Positive	Liver	IV	T4NxM1	FOLFOX+trastuzumab
4	70	Female	Cardia	5	Poor	Positive	Liver	IV	T4bNxM1	FOLFOX+trastuzumab
5	71	Male	Body	6.5	Poor	Positive	Liver	IV	T4N1M1	FOLFOX+trastuzumab
6	65	Male	Body	5.5	Moderate	Positive	Peritoneum	IV	T4bN1M1	FOLFOX+trastuzumab
7	79	Male	Antrum	4	Moderate	Positive	Liver	IV	T4N1M1	FOLFOX+trastuzumab
8	72	Male	Antrum	5	Poor	Positive	Liver	IV	T4N1M1	FOLFOX+trastuzumab
9	56	Male	Cardia	4	Moderate	Positive	Peritoneum	IV	T4bN1M1	FOLFOX+trastuzumab
10	59	Female	Cardia	5	Moderate	Positive	Liver	IV	T4aNxM1	FOLFOX+trastuzumab
11	64	Female	Body	4	Poor	Positive	Peritoneum	IV	T4N1M1	FOLFOX+trastuzumab
12	72	Male	Antrum	4.5	Moderate	Positive	Liver	IV	T4N1M1	FOLFOX+trastuzumab

FOLFOX = oxaliplatin (L-OHP)+calcium folinate (CF)+5-fluorouracil (5-Fu).